In this episode of Lung Cancer Considered, host Dr. Narjust Florez explores controversies in managing lung cancer patients with comorbidities – those often un ...

Stage III NSCLC is now a moving target! This webinar will address key practice gaps and real-world decision points in the radiotherapy management of locally adv ...

Nogapendekin alfa combination gains accelerated approval in Saudi Arabia for metastatic NSCLC.

Join us at the IASLC 2026 World Conference on Lung Cancer (WCLC 2026) in Seoul, Republic of South Korea, from September 12–15, 2026.

Committee Chair Dr. Ross Soo addresses its role in supporting the IASLC’s mission of providing relevant, impactful, and timely educational content on a global scale.

As part of IASLC’s ongoing series of Lung Cancer Considered podcasts in world languages, Dr. Molly Li moderates a discussion in Cantonese with two expert card ...

This episode of Lung Cancer Considered takes an in-depth look at AI in lung cancer care. Join host Dr. Narjust Florez and Dr. Sandip Patel for a discussion of t ...

Dr. Stephen Liu recently highlighted the safety and efficacy of a targeted therapy for patients with NRG1-positive cancers with updated data from the ongoing eNRGy trial.

In the conclusion of this two-part series, Drs. Tomasik and Dziadziuszko highlight unresolved questions and future directions for integrating HA-PCI and SRS into practice for SCLC.

Patient advocate Kate Sinclair shares why communication is one of the most important tools for improving the patient experience during their lung cancer journey.

The US FDA grants special designation to risvutatug rezetecan for SCLC and approves the subcutaneous formulation of amivantamab plus hyaluronidase-lpuj for EGFR+ NSCLC.

Experts outline how Poland aims to reduce lung cancer mortality while addressing one of the nation’s most persistent health challenges: tobacco dependence.

Drs. Tomasik and Dziadziuszko discuss how the SCLC field is shifting toward brain-sparing techniques to maximize disease control, as well as cognitive preservation.

In a Q&A with ILCN, Dr. Gilberto de Lima Lopes, Committee Chair, details how the committee is working to address the most significant global challenges in lung cancer care.

In this episode of Lung Cancer Considered, host Dr. Stephen Liu is joined by CNN Medical Correspondent Meg Tirrell and WTOP reporter Neal Augenstein to discuss ...

In this episode of Lung Cancer Considered, host Dr. Stephen Liu is joined by Dr. Jarushka Naidoo for an in-depth discussion of immunotherapy in lung cancer, spe ...

Dr. Scott Laurie recently presented data from IND227 that showed the combination improved overall survival by 24% compared with chemotherapy alone.

Lead investigator Dr. Kelly Paulson said the combination demonstrated unprecedented overall survival with a manageable safety profile in this patient population.

A real-world example of the progress that has been made in lung cancer care, ILCN editorial group member and contributor Angus Pratt survived more than seven years after his lung cancer diagnosis.

In this special episode of Lung Cancer Considered, Dr. Narjust Florez and Dr. Stephen Liu discuss highlights from the IASLC | ASCO 2025 North America Conference ...

Lead author, Dr. Mihaela Aldea, discusses how the IASLC's recently published consensus statement could strengthen new and established molecular tumor boards.

Cutting-edge research, vigorous debates, and a healthy dose of humor and collegiality are all on tap for the 2025 North American Conference on Lung Cancer, which will be held in Chicago, Dec. 5–9.